Skip to main content
. Author manuscript; available in PMC: 2012 May 15.
Published in final edited form as: Clin Cancer Res. 2011 Mar 8;17(10):3181–3192. doi: 10.1158/1078-0432.CCR-10-2874

Figure 5.

Figure 5

Drozitumab (DRO) has potent anti-tumor activity and a specificity predicted by our in vitro results. A. Both sensitive Rh18 and resistant Rh41 were inoculated intramuscularly into SCID mice. After 4–5 weeks, when tumors just became palpable, mice were treated with 10 mg/kg i.p. drozitumab or placebo antibody alone once weekly. The size of the tumors was measured and shown (n=10). B. Mice with sensitive Rh18 tumors were treated with drozitumab or placebo for 4 days. Tumors were resected, and stained with H&E and TUNEL for apoptotic cells. C. Kaplan-Meier survival analysis of the Rh18- or Rh41-tumor bearing mice treated with drozitumab or placebo. The administration of drozitumab for Rh18 was stopped after 10 weeks and the mice were followed for another 18 weeks without treatment until all mice that developed visible tumors died.